ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell therapy

Last month, Bristol Myers Squibb made the surprise announcement that the FDA will convene an advisory committee meeting to discuss the company’s bid to move the CAR-T therapy Abecma into earlier lines of treatment. Now, we know at least one reason why the FDA wants more opinions on the application.